<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Multidrug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) phenotype expression was evaluated retrospectively in 87 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 69 with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ten with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and eight with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="14" ids="53218">MDR</z:chebi> phenotype, characterized by P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> expression (MRK16 monoclonal antibody) and decrease in intracellular <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (DNR) accumulation was determined using flow cytometry </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received chemotherapy including <z:chebi fb="1" ids="16040">cytosine</z:chebi>-<z:chebi fb="0" ids="22601">arabinoside</z:chebi> and <z:chebi fb="0" ids="48120">anthracycline</z:chebi> (<z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, zorubicin, <z:chebi fb="0" ids="42068">idarubicin</z:chebi>) or <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>, and <z:chebi fb="56" ids="15854">quinine</z:chebi> in ten cases </plain></SENT>
<SENT sid="3" pm="."><plain>The predictive value of the <z:chebi fb="14" ids="53218">MDR</z:chebi> phenotype for clinical responsiveness was studied using uni- and multivariate analyses </plain></SENT>
<SENT sid="4" pm="."><plain>Univariate analysis showed that DNR accumulation (p &lt; 10(-4)), P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> expression (p = 10(-4)) and disease status (de novo versus recurrent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (p = 10(-4)) were predictive of clinical responsiveness </plain></SENT>
<SENT sid="5" pm="."><plain>The significance of these three parameters was maintained in multivariate analysis </plain></SENT>
<SENT sid="6" pm="."><plain>When de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was considered, only DNR accumulation was of predictive value (p &lt; 10(-4)) for complete response to chemotherapy </plain></SENT>
</text></document>